2020 年 4 月至 2021 年 8 月美国门诊环境中 COVID-19 患者使用全身性皮质类固醇的情况。
Systemic Corticosteroid Use for COVID-19 in US Outpatient Settings From April 2020 to August 2021.
机构信息
Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland.
Acumen LLC, Burlingame, California.
出版信息
JAMA. 2022 May 24;327(20):2015-2018. doi: 10.1001/jama.2022.4877.
Abstract
This study uses 2 large US health care claims databases (Medicare fee-for-service and the US Food and Drug Administration’s Sentinel System) to examine systemic corticosteroid use among nonhospitalized patients with COVID-19.
摘要
本研究使用了两个大型美国医疗保健索赔数据库（医疗保险按服务收费和美国食品和药物管理局的 Sentinel 系统），以研究非住院 COVID-19 患者中全身皮质类固醇的使用情况。
相似文献
1
Systemic Corticosteroid Use for COVID-19 in US Outpatient Settings From April 2020 to August 2021.2020 年 4 月至 2021 年 8 月美国门诊环境中 COVID-19 患者使用全身性皮质类固醇的情况。
JAMA. 2022 May 24;327(20):2015-2018. doi: 10.1001/jama.2022.4877.
2
Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.COVID-19 肺炎的糖皮质激素（CORTIVID）治疗：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):43. doi: 10.1186/s13063-020-04999-4.
3
Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2, Update Alert).
Ann Intern Med. 2024 Aug;177(8):e2400141. doi: 10.7326/ANNALS-24-00141. Epub 2024 Jul 9.
4
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2, Update Alert).确诊新型冠状病毒肺炎的门诊治疗：美国医师协会的实用快速要点（第2版，更新警报）
Ann Intern Med. 2024 Aug;177(8):e2400128. doi: 10.7326/ANNALS-24-00128. Epub 2024 Jul 9.
5
Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study.托珠单抗或糖皮质激素治疗 SARS-CoV-2 肺炎患者：一项观察性研究。
Braz J Infect Dis. 2022 Jan-Feb;26(1):101702. doi: 10.1016/j.bjid.2021.101702. Epub 2021 Dec 21.
6
Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.轻症肺炎患者无需住院的情况下使用类固醇进行 COVID-19 门诊治疗作为改变疾病进程的机会：一项随机对照试验的结构化总结。
Trials. 2020 Jul 9;21(1):632. doi: 10.1186/s13063-020-04575-w.
7
Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection.高危 SARS-CoV-2（COVID-19）感染患者早期门诊多药物治疗后的临床结局。
Rev Cardiovasc Med. 2020 Dec 30;21(4):611-614. doi: 10.31083/j.rcm.2020.04.260.
8
Systemic glucocorticoids link to long-term microvascular injury in COVID-19.全身糖皮质激素与新冠病毒感染（COVID-19）的长期微血管损伤有关。
Angiogenesis. 2024 Aug;27(3):285-286. doi: 10.1007/s10456-024-09923-x. Epub 2024 Apr 24.
9
Perspectives on glucocorticoid treatment for COVID-19: a systematic review.关于 COVID-19 糖皮质激素治疗的观点：系统评价。
Pharmacol Rep. 2021 Jun;73(3):728-735. doi: 10.1007/s43440-021-00225-3. Epub 2021 Mar 5.
10
Use of glucocorticoids and azithromycin in the therapy of COVID-19.COVID-19 的糖皮质激素和阿奇霉素治疗。
Pharmacol Rep. 2021 Dec;73(6):1513-1519. doi: 10.1007/s43440-021-00286-4. Epub 2021 Jun 4.
引用本文的文献
1
Infection to hypertension: a review of post-COVID-19 new-onset hypertension prevalence and potential underlying mechanisms.感染与高血压：COVID-19后新发高血压患病率及潜在机制综述
Front Cardiovasc Med. 2025 Aug 18;12:1609768. doi: 10.3389/fcvm.2025.1609768. eCollection 2025.
2
Increasing the Utility of Real-World Data to Inform Public Health Decision Making Through a US-based Private-Public Partnership: 10 Lessons Learned from a Principled Approach to Rapid Pandemic RWE Generation.通过美国的公私伙伴关系提高真实世界数据在为公共卫生决策提供信息方面的效用：从快速大流行真实世界证据生成的原则性方法中学到的十条经验教训。
Ther Innov Regul Sci. 2025 May;59(3):629-641. doi: 10.1007/s43441-025-00748-4. Epub 2025 Mar 18.
3
Collaborative Real-World Evidence Among Regulators: Lessons and Perspectives.监管机构间的合作性真实世界证据：经验与观点
Clin Pharmacol Ther. 2025 Feb;117(2):368-373. doi: 10.1002/cpt.3457. Epub 2024 Oct 21.
4
Post-COVID-19 condition symptoms among emergency department patients tested for SARS-CoV-2 infection.急诊患者新冠病毒感染检测后的新冠后症状。
Nat Commun. 2024 Sep 30;15(1):8449. doi: 10.1038/s41467-024-52404-4.
5
Comparative effectiveness of dexamethasone in treatment of hospitalized COVID-19 patients in the United States during the first year of the pandemic: Findings from the National COVID Cohort Collaborative (N3C) data repository.在大流行的第一年，美国住院 COVID-19 患者中地塞米松治疗的疗效比较：来自国家 COVID 队列协作（N3C）数据存储库的研究结果。
PLoS One. 2024 Mar 21;19(3):e0294892. doi: 10.1371/journal.pone.0294892. eCollection 2024.
6
Corticosteroid treatment for persistent pulmonary infiltrates following COVID-19 infection: Clearing the fog?新冠病毒感染后持续性肺部浸润的皮质类固醇治疗：拨开迷雾？
Ann Thorac Med. 2024 Jan-Mar;19(1):74-80. doi: 10.4103/atm.atm_121_23. Epub 2024 Jan 25.
7
Bacterial Proteases as Potentially Exploitable Modulators of SARS-CoV-2 Infection: Logic from the Literature, Informatics, and Inspiration from the Dog.细菌蛋白酶作为新冠病毒感染潜在可利用的调节剂：来自文献的逻辑、信息学以及犬类的启示
BioTech (Basel). 2023 Oct 30;12(4):61. doi: 10.3390/biotech12040061.
8
Treating COVID-19: Targeting the Host Response, Not the Virus.治疗新冠病毒病：针对宿主反应，而非病毒。
Life (Basel). 2023 Mar 6;13(3):712. doi: 10.3390/life13030712.
9
The US Food and Drug Administration Sentinel System: a national resource for a learning health system.美国食品和药物管理局监测系统：学习型卫生系统的国家资源。
J Am Med Inform Assoc. 2022 Nov 14;29(12):2191-2200. doi: 10.1093/jamia/ocac153.
Zotero 插件